* Mirapexin® is a registered trademark of Boehringer Ingelheim Ltd.
1 Pipexus (pramipexole dihydrochloride monohydrate). Public assessment report. SE/H/1558/01-07/DC. June 2016.
2 Drug Tariff March 2015 (England and Wales).
3 Data on file.
4 Price guarantee for all products within the current PPRS Agreement (April 2019)
† Dose strengths are quoted as pramipexole base (without dihydrochloride monohydrate salts).
A bracketing approach is considered acceptable for 1.05, 1.57, 2.10, and 2.62 mg dose strength bioequivalence with Mirapexin®.
Pipexus® is bioequivalent to Mirapexin® and with a 50% saving*1,2
Ethypharm UK will guarantee that the price of Pipexus® will not increase, subject to there being no material change to the PPRS or Category C of the Drug Tariff, outside the control of Ethypharm. 4
Available through main line wholesalers AAH and Phoenix.